CLVS News and Press, Clovis Oncology Inc. From 05/04/22

Gainers: Sharps Technology (STSS) +43%. TransMedics Group (TMDX) +30%. Super Micro Computer (SMCI) +25%. CarParts.com (PRTS) +25%. Superior Industries International (SUP) +22%. Livent (LTHM) +23%. Bright Health Group (BHG) +21%. eHealth (EHTH) +19%. BlueLinx Holdings (BXC) +18%. Kimball Inter...

Clovis Oncology, Inc. (CLVS) Q1 2022 Earnings Conference Call May 4, 2022, 08:30 AM ET Company Participants Anna Sussman - VP, IR and Corporate Communications Patrick Mahaffy - President and CEO Thomas Harding - Chief Scientific Officer Dan Muehl - CFO Conference Call Participants Charlie Fer...

Shares of Clovis Oncology (NASDAQ:CLVS) are down 23% in Wednesday morning trading after its Q1 2022 results missed on both the top and bottom lines amid a decline in sales of its key product Rubraca (rucaparib). The company's net loss narrowed 9% in Q1 to -$60.2M (-$0.44 vs. -$0.64 ...

Palm Beach, FL – May 4, 2022 – FinancialNewsMedia.com News Commentary – Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years and will continue in the years to come. Breast cancer ...

Clovis Oncology press release (NASDAQ:CLVS): Q1 GAAP EPS of -$0.44 misses by $0.05. Revenue of $34.25M (-10.0% Y/Y) misses by $2.74M. $122.2M in cash and cash equivalents and $18.6M in available funding under the ATHENA financing at March 31, 2022 Shares +0.95% PM. Cash burn  was $49.3 m...

ATHENA study evaluating Rubraca ® (rucaparib) monotherapy versus placebo (ATHENA-MONO) in first-line ovarian cancer maintenance treatment successfully achieved the primary endpoint of improved PFS in both populations in the primary efficacy analyses: HRD-positive and all pa...

Clovis Oncology (NASDAQ:CLVS) is scheduled to announce Q1 earnings results on Wednesday, May 4th, before market open. The consensus EPS Estimate is -$0.49 (+23.4% Y/Y) and the consensus Revenue Estimate is $36.99M (-2.8% Y/Y). Over the last 3 months, EPS estimates have seen 0 upward revi...

Includes presentation of additional late-breaking Phase 3 ATHENA-MONO trial data as complement to previously announced topline data Clovis Oncology, Inc. (NASDAQ: CLVS), announced today that seven abstracts from the company’s pipeline, including late-breaking data fro...

The steep decline in Myovant Sciences share price is due to an FDA notice regarding relugolix label expansion for endometriosis. Irrespective of the FDA decision, I strongly believe that relugolix will ultimately gain approval for endometriosis (perhaps in either Q3 or Q4 this year). ...

Clovis, a "trading stock," has some shakiness in its fundamentals. Moreover, the shares tend to rise and fall for you to trade for short-term gains. Due to upcoming catalysts in June, Clovis is a trading stock that is about to embark on another bullish cycle. Despite being a tradi...